Nkarta, Inc. (NASDAQ:NKTX) Stock Has Consensus Target Price of $11.20 According to Brokerages

Posted by Brenda Bartman on Oct 3rd, 2026

Nkarta, Inc. (NASDAQ:NKTX – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the seven analysts that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $11.20.

NKTX has been the topic of a number of recent analyst reports. Stifel Nicolaus reduced their price objective on Nkarta from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, August 14th. HC Wainwright decreased their target price on Nkarta to $14.00 and set a “buy” rating on the stock in a report on Tuesday, August 11th. TD Cowen began coverage on Nkarta in a research note on Tuesday, June 23rd. They issued a “buy” rating for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nkarta in a report on Monday, September 21st. Finally, Wall Street Zen downgraded shares of Nkarta from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th.

View Our Latest Stock Analysis on Nkarta

Nkarta Trading Up 0.8%

NASDAQ:NKTX opened at $2.58 on Monday. Nkarta has a 1 year low of $1.70 and a 1 year high of $3.72. The firm has a 50 day moving average of $2.60 and a 200-day moving average of $2.69. The stock has a market capitalization of $184.79 million, a P/E ratio of -1.64 and a beta of 0.93.

Nkarta (NASDAQ:NKTX – Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.18). As a group, analysts forecast that Nkarta will post -1.6 EPS for the current fiscal year.

Hedge Funds Weigh In On Nkarta

Institutional investors have recently modified their holdings of the stock. Monaco Asset Management SAM bought a new stake in shares of Nkarta during the second quarter valued at approximately $6,717,000. BlackRock Inc. acquired a new stake in shares of Nkarta in the second quarter valued at approximately $17,830,000. AWM Investment Company Inc. bought a new position in Nkarta in the 2nd quarter worth approximately $2,564,000. Forefront Analytics LLC bought a new position in Nkarta in the 2nd quarter worth approximately $82,000. Finally, GSA Capital Partners LLP bought a new position in Nkarta in the 2nd quarter worth approximately $321,000. 80.54% of the stock is owned by institutional investors.

Nkarta Company Profile

(Get Free Report)

Nkarta, Inc is a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies for the treatment of cancer. The company’s approach is designed to use allogeneic, or donor-derived, immune cells that can be manufactured for use across multiple patients, with the goal of providing an off-the-shelf alternative to individualized cell therapies.

Nkarta’s product candidates include NKX101, an engineered CAR NK cell therapy designed to recognize NKG2D ligands expressed on certain cancer cells, and NKX019, a CD19-targeted CAR NK cell therapy being developed for B-cell malignancies.